A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of TecfideraTM (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM) Save

Date Added
June 5th, 2014
PRO Number
Pro00035485
Researcher
Davit Mrelashvili
Keywords
Multiple Sclerosis
Summary

The primary objective of the study is to determine the incidence, type, and pattern of serious adverse events, including but not limited to serious infections (including opportunistic infections), hepatic events, malignancies, and renal events, and of adverse events leading to treatment discontinuation, in patients with MS treated with DMF. Secondary study objectives are to (1) determine DMF prescription and utilization patterns in routine clinical practice in patients with MS; (2) assess the effectiveness of DMF on MS disease activity and disability progression; and (3) assess the effect of DMF on patient health-related quality of life, healthcare resource consumption, and work productivity.

Institution
USC
Recruitment Contact
Alyson Grant
803-545-6104
alyson.grant@uscmed.sc.edu

Change_preferences

-- OR --

Create_login